Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04662879
Other study ID # 466
Secondary ID FHIRB0010533RG10
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 14, 2021
Est. completion date July 2030

Study information

Verified date July 2023
Source Pancreatic Cancer Action Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Early Detection Initiative for Pancreatic Cancer is a multi-center randomized controlled trial to determine if algorithm-based screening in patients with new onset hyperglycemia and diabetes can result in earlier detection of pancreatic ductal adenocarcinoma.


Description:

The Early Detection Initiative (EDI), is designed to evaluate if imaging at the time of new onset hyperglycemia and diabetes, especially at its earliest discovery through passive surveillance of the electronic medical record (EMR), results in earlier detection of pancreatic ductal adenocarcinoma (PDAC). Eligible patients are identified and enrolled based on a first-time elevation in fasting blood glucose or glycated hemoglobin (HbA1c) to the level indicating diabetes as derived from records in their EMR. All enrolled patients are randomized to either the Observational Arm or Intervention Arm of the study. Patients randomized to the Intervention Arm have Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated using age, body weight and glucose or glycated hemoglobin values in their EMR. Patients with high ENDPAC score (>0) are approached for informed consent to participate in up to two imaging studies by computerized tomography (CT) scan or magnetic resonance imaging (MRI). In addition to imaging, participants will be asked to complete study questionnaires and participate in serial blood collection at up to five time points. Blood samples collected in the EDI study will contribute to the National Institutes of Health (NIH) National Cancer Institute (NCI) biorepository located at the Frederick National Laboratory for Cancer Research facility. Patients in both study arms are followed for development of PDAC. This study is performed at locations with broad (institutional) consent for use of patient EMR information for research studies. Passive follow-up by EMR will occur for five years following enrollment. Any patient that has declined participation in EMR-based research at the institution is not included in the study.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 12500
Est. completion date July 2030
Est. primary completion date July 2030
Accepts healthy volunteers No
Gender All
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria: - Patient must have given institutional consent for minimal risk studies. - Patient must be =50 and =85 years of age at the time of diagnosis [index date Parameters of Diabetes Mellitus (PDM)]. - Patient must have index weight and left-window weight values available in electronic medical record (EMR). - Patient must have hyperglycemia and/or diabetes as one of the following =90 days prior to randomization (all glycemic parameters, except for HbA1c, must be measured in an outpatient setting): A. Glycated hemoglobin (HbA1c) = 6.5% OR B. Any (2) PDMs on consecutive (=90 days between PDMs) or simultaneous testing: - Fasting Blood Glucose (FBG) =126 mg/dl - Glycated hemoglobin (HbA1c) = 6.5% - Random Blood Glucose (RBG) =200 mg/dl - 2 hour Post Glucose (PG) = 200mg (11.1 mmol/L) during oral glucose tolerance test (OGTT) OR C. Any one (1) PDM present followed by an anti- diabetes medication =90 days after the index PDM date - Patient must have =1 glycemic parameter measured in the past 91-548 days prior to the index PDM date (Left Window) without meeting inclusion criteria A, B, or C. Exclusion Criteria: - Patient has declined institutional consent for minimal risk studies. - Patient must not have any known past history of hyperglycemia and/or diabetes as defined by inclusion criteria A, B, or C *Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion. - Patient must not be on active treatment for cancer, carry a current diagnosis of any cancer, and/or investigated for suspicion of recurrence of past cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix). *Ongoing work up for suspicion of pancreatic cancer is not an exclusion. - Patient must not have had a definitive diagnosis of pancreatic cancer prior to index PDM date. - Patient must not be on any anti-diabetes medications prior to index PDM date. - Patient must not be on chronic or acute use of steroid medications =90 days prior to the index PDM date. *Allowed: Nasal, topical steroids, oral budesonide, ophthalmic - Patient must not have had an intra-articular steroid injection = 7 days prior to the index PDM date.

Study Design


Intervention

Other:
Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score
ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.
Abdominal imaging
Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.

Locations

Country Name City State
United States Baylor College of Medicine Houston Texas
United States Kaiser Permanente Southern California, Kaiser Permanente Research Pasadena California

Sponsors (3)

Lead Sponsor Collaborator
Pancreatic Cancer Action Network Fred Hutchinson Cancer Center, National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005 Aug;129(2):504-11. doi: 10.1016/j.gastro.2005.05.007. — View Citation

Chen W, Butler RK, Lustigova E, Chari ST, Wu BU. Validation of the Enriching New-Onset Diabetes for Pancreatic Cancer Model in a Diverse and Integrated Healthcare Setting. Dig Dis Sci. 2021 Jan;66(1):78-87. doi: 10.1007/s10620-020-06139-z. Epub 2020 Feb 28. — View Citation

Khan S, Safarudin RF, Kupec JT. Validation of the ENDPAC model: Identifying new-onset diabetics at risk of pancreatic cancer. Pancreatology. 2021 Apr;21(3):550-555. doi: 10.1016/j.pan.2021.02.001. Epub 2021 Feb 8. — View Citation

Sharma A, Kandlakunta H, Nagpal SJS, Feng Z, Hoos W, Petersen GM, Chari ST. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018 Sep;155(3):730-739.e3. doi: 10.1053/j.gastro.2018.05.023. Epub 2018 Jun 11. — View Citation

Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018 Aug;155(2):490-500.e2. doi: 10.1053/j.gastro.2018.04.025. Epub 2018 Apr 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Earlier detection of pancreatic ductal adenocarcinoma (PDAC) Determine if algorithm-based screening in new onset hyperglycemia and diabetes (NOD) results in earlier detection of pancreatic ductal adenocarcinoma (PDAC) as evidenced by a lower proportion of Stage III/IV disease at the time of PDAC diagnosis in intervention vs observation arm. Baseline and approximately every six months for up to five years
Secondary Smaller proportion of unresectable disease Determine if Intervention results in earlier detection of PDAC defined as a smaller proportion of unresectable disease. Baseline and approximately every six months for up to five years
Secondary Less Stage IV disease Determine if Intervention results in earlier detection of PDAC defined as less Stage IV disease. Baseline and approximately every six months for up to five years
Secondary Smaller proportion with advanced pancreatic cancer symptoms Determine if Intervention results in earlier detection of PDAC defined as a smaller proportion with advanced pancreatic cancer symptoms. Baseline and approximately every six months for up to five years
Secondary Estimating risk in subgroups Estimate the risk of PDAC in NOD and Enriching New-onset Diabetes (or hyperglycemia) for Pancreatic Cancer (ENDPAC) subgroups. Baseline and approximately every six months for up to five years
Secondary Validate ENDPAC model Prospectively validate the ENDPAC model. Baseline and approximately every six months for up to five years
Secondary Over diagnosis due to imaging intervention of NOD Determine the magnitude of over diagnosis due to imaging intervention of NOD. Baseline and imaging follow-up visit, up to 9 months
Secondary Determine the proportion of incidental findings Determine, on imaging in NOD, the proportion with incidental findings that require clinical workup. Baseline and approximately every six months for up to five years
Secondary Contribute to NOD biobank Contribute blood biospecimens to a previously established NOD cohort biobank for future biomarker validation studies. Baseline and blood collection follow-up visits, up to 36 months
Secondary Depression and Anxiety as early indicators Determine if symptoms of depression and anxiety are early indicators of PDAC. Baseline and follow-up visits
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A